Endogenex has successfully secured $50 million in venture capital to advance its minimally invasive treatment for Type 2 diabetes, aiming for FDA approval. This funding follows promising clinical results demonstrating that its pulsed electric field system not only met safety benchmarks but also achieved significant metabolic improvements in participants, including reductions in HbA1c and body weight.

The company, established in collaboration with the Mayo Clinic, targets the duodenum to address the underlying dysfunction associated with Type 2 diabetes. By delivering pulsed electric fields to the mucosal layers, Endogenex’s approach eliminates poorly functioning cells while stimulating regeneration, offering a new avenue for managing a disease that often progresses despite existing therapies. The recent clinical trial published in Diabetes, Obesity and Metabolism highlighted a 100% technical success rate and substantial metabolic benefits over 48 weeks.

This funding will facilitate the pivotal ReCET trial, which could redefine treatment paradigms by addressing gut health in diabetes management. As Endogenex moves closer to FDA approval, its innovative approach could significantly impact the future of Type 2 diabetes therapeutics.

Source: fiercebiotech.com